廣田集團(002482.SZ):將持續關注陸寧支付業績補償款的情況
格隆匯 6 月 29日丨廣田集團(002482.SZ)公佈,截至公告日,陸寧已將其持有的南京柏森的10%股權轉讓給廣田集團,並於2017年12月28日辦理完畢工商變更登記手續;陸寧已向南京柏森支付了補償款2100萬元,目前,尚有補償款2400萬元未支付。詳細情況請參見公司於2018年8月25日披露的《關於控股子公司業績承諾補償進展公告》。
截至目前,陸寧尚持有公司股票共521.6937萬股,全部為限售股。公司將持續關注陸寧支付業績補償款的情況,督促其按照《股權轉讓補充協議》的約定支付補償金,並根據業績補償完成情況對其持有的尚未解除限售的公司股份521.6937萬股解除限售。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.